Skip to main content

Table 4 Levels of the peripheral blood markers by irAEs development

From: Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy

Blood parameter

irAEs, n(%)

Univariate

Multivariate

OR(95%CI)

P

OR(95%CI)

P

NLR<5(n=103)

34(33.00)

0.739(0.320-1.79)

0.480

0.383(0.125-1.178)

0.094

NLR>5(n=30)

12(40.00)

1

 

1

 

PLR<135(n=53)

14(26.42)

0.538(0.253-1.148)

0.109

0.605(0.274-1.338)

0.215

PLR>135(n=80)

32(40.00)

1

 

1

 

MLR<0.31(n=64)

27(42.19)

1.920(0.930-3.964)

0.078

1.138(0.501-1.583)

0.059

MLR>0.31(s69)

19(27.54)

1

 

1

 
  1. OR Odds ratio, CI Confidence interval, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio, MLR Monocyte-to-lymphocyte ratio, irAEs Immune-related adverse events
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us